Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Kura Oncology (KURA) Invested Capital (2023 - 2025)

Kura Oncology (KURA) has disclosed Invested Capital for 3 consecutive years, with $183.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Invested Capital fell 55.84% to $183.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $183.8 million, a 55.84% decrease, with the full-year FY2025 number at $183.8 million, down 55.84% from a year prior.
  • Invested Capital was $183.8 million for Q4 2025 at Kura Oncology, down from $246.9 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $505.1 million in Q1 2024 to a low of $183.8 million in Q4 2025.
  • A 3-year average of $383.5 million and a median of $406.8 million in 2023 define the central range for Invested Capital.
  • Peak YoY movement for Invested Capital: grew 27.81% in 2024, then plummeted 55.84% in 2025.
  • Kura Oncology's Invested Capital stood at $397.3 million in 2023, then grew by 4.78% to $416.2 million in 2024, then tumbled by 55.84% to $183.8 million in 2025.
  • Per Business Quant, the three most recent readings for KURA's Invested Capital are $183.8 million (Q4 2025), $246.9 million (Q3 2025), and $308.6 million (Q2 2025).